Table 2 Methotrexate history of study patients

Age in years at starting MTX, mean (S.D.) (n=168)

6.1 (3.9)

Duration in months of MTX use, median (IQR)

29.0 (11.5 – 60.5)

Current MTX dose (mg/m²/week), median (IQR)

12.5 (10 – 15)

MTX route, n (%)

Oral route throughout

55 (32.2)

Current route oral but previously subcutaneous

16 (9.4)

Subcutaneous route throughout

24 (14.0)

Current route subcutaneous but previously oral

76 (44.4)